aprott/iStock via Getty Images
Noom, an online weight-loss company, said on Monday that it will offer copies of Novo Nordisk’s (NVO) obesity drug Wegovy at a starting price of $119 for a quarter of the standard dose, providing a more affordable option for patients to try the medication.
After the initial month, the price will increase up to $199 per month for a maximum dose of 0.6 milligrams, in contrast to the typical branded dose of 2.4 mg.
Noom also recently launched its GLP-1Rx program, which provides compounded versions of semaglutide, the active ingredient of Wegovy, at a maximum dose of 1.2 mg for $149 in the first month and $279 thereafter.
Noom’s competitor, Hims and Hers Health (HIMS), provides a one-year prepaid program for compounded semaglutide at $199 per month.
Noom also offers Eli Lilly’s weight loss therapy, Zepbound (LLY) for $349 through Lilly Direct, along with generic versions of Novo’s (NVO) older weight loss injectable, liraglutide.
More on Novo Nordisk
- Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside
- Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
- Novo Nordisk: Don’t Miss Buying This Dip
- Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks
- Novo Nordisk gets FDA expanded approval for hemophilia treatment